BioSpace News Archive

Epitome Risk announces its at-home neutralizing antibody test is now sold online.

The Thrombosis Research Institute has six atrial fibrillation e-posters – four from the GARFIELD-AF Registry and two from the RIVER Registry – at the European Society of Cardiology Congress 2021, which is taking place virtually from 27th to 30th August 2021.

Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, is investing an additional USD 25 million in the U.S. medical company Humacyte, Inc.

Exactech, today announced first surgeries using Newton™, an innovative soft tissue management technology that combines dynamic ligament balancing and real-time guidance to bring to life a personalized intraoperative solution designed to improve total knee replacement surgery outcomes and patient satisfaction.

PreciseMDX, the leading end-to-end digital health platform, introduces a cloud-based solution that automates and simplifies the diagnostic testing experience, empowering labs to deliver a transformative journey to providers and patients.

David joins PharmaDrug after nearly 20 years of combined industry and capital markets experience, most recently serving as Managing Director, Senior Institutional Equity Research Analyst at ATB Capital Markets.

Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, announced that it is scheduled to speak at the Morgan Stanley 19th Annual Global Healthcare Conference.

BPK is using an innovative concept of ROR1 CAR T-cell therapy combined with a double specific antibody model. In conjunction with the development of it’s own CAR T, the Company plans to apply for patents covering this CAR T-cell cancer therapy technology.

CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the publication entitled “Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model” in the peer-reviewed Journal of Hepatology.

Viva Biotech Holdings (1873.HK) announced that during the period ended June 30, 2021 (the “Reporting Period”), revenue of the Group increased significantly to RMB1,026.5 million from RMB197.6 million for the corresponding period last year